Tag archive for ‘Oncology’
AbbVie reported that ibrutinib, venetoclax combo has met the primary endpoint of PFS in phase 3 GLOW study in chronic lymphocytic leukemia
By businessnewstoday On Sunday, June 13th, 2021
0 Comments

AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study

(adsbygoogle = window.adsbygoogle || []).push({}); AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus More...

Amgen LUMAKRAS FDA approval - LUMAKRAS product shot
By businessnewstoday On Saturday, May 29th, 2021
0 Comments

LUMAKRAS FDA approval : Amgen bags approval in KRAS G12C-mutated NSCLC

LUMAKRAS FDA approval : Amgen has bagged accelerated approval from the US Food and Drug Administration (FDA) for LUMAKRAS (sotorasib) for the treatment of a type of non-small cell lung cancer (NSCLC) in adults. The More...

Chronos-3 trial results : Aliqopa, rituximab combo meets primary endpoint of PFS, says Bayer
By businessnewstoday On Sunday, April 11th, 2021
0 Comments

Chronos-3 trial results : Aliqopa, rituximab combo meets primary endpoint of PFS, says Bayer

Chronos-3 trial results : Bayer said that the investigational combination of Aliqopa (copanlisib) and rituximab considerably increased progression-free survival (PFS) in patients having relapsed indolent non-Hodgkin’s More...

Pyxis Oncology raises $152m in Series B round for cancer therapies
By businessnewstoday On Tuesday, March 30th, 2021
0 Comments

Pyxis Oncology raises $152m in Series B round for cancer therapies

Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, More...

Bristol Myers Squibb, bluebird bio bag Abecma FDA approval for multiple myeloma in adults
By businessnewstoday On Sunday, March 28th, 2021
0 Comments

BMS, bluebird bio bag Abecma FDA approval for multiple myeloma in adults

Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food and Drug Administration (FDA) for Abecma (idecabtagene vicleucel; ide-cel) for the treatment of relapsed or More...

French biotech company Step Pharma raises €35m in a Series B round
By businessnewstoday On Wednesday, March 24th, 2021
0 Comments

French biotech company Step Pharma raises €35m in a Series B round

Step Pharma has raised €35 million in a Series B financing round for advancing STP938, its lead CTPS1 inhibitor into clinical development for the treatment of T-cell malignancies. The French biotech company is More...

Aura Biosciences raises $80m for VDC therapies for cancers
By businessnewstoday On Monday, March 22nd, 2021
0 Comments

Aura Biosciences raises $80m for VDC therapies for cancers

Aura Biosciences, a portfolio company of UK-based Arix Bioscience, has raised $80 million in a new funding round for developing virus-like drug conjugate (VDC) therapies for multiple oncology indications. The funding More...

Anixa Biosciences files IND with FDA for ovarian cancer CAR-T therapy
By businessnewstoday On Monday, March 22nd, 2021
0 Comments

Anixa Biosciences files IND with FDA for ovarian cancer CAR-T therapy

Anixa Biosciences said that it has filed an investigational new drug (IND) application for its ovarian cancer CAR-T therapy with the US Food and Drug Administration (FDA). The ovarian cancer CAR-T therapy was invented More...

Amgen acquisition of Five Prime Therapeutics
By businessnewstoday On Thursday, March 4th, 2021
0 Comments

Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab

Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add a phase 3 ready gastric cancer candidate called More...

Agilent Technologies to acquire Resolution Bioscience in $695m worth deal
By businessnewstoday On Tuesday, March 2nd, 2021
0 Comments

Agilent Technologies to acquire Resolution Bioscience in $695m worth deal

Agilent Technologies, a US analytical instrumentation development and manufacturing company, has agreed to acquire Resolution Bioscience in a deal worth up to $695 million. Resolution Bioscience is a next generation More...